Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

43 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Two Secreted Proteoglycans, Activators of Urothelial Cell-Cell Adhesion, Negatively Contribute to Bladder Cancer Initiation and Progression.
Papadaki V, Asada K, Watson JK, Tamura T, Leung A, Hopkins J, Dellett M, Sasai N, Davaapil H, Nik-Zainal S, Longbottom R, Nakakido M, Torii R, Veerakumarasivam A, Kaneko S, Sagoo MS, Murphy G, Mitani A, Tsumoto K, Kelly JD, Hamamoto R, Ohnuma SI. Papadaki V, et al. Among authors: veerakumarasivam a. Cancers (Basel). 2020 Nov 13;12(11):3362. doi: 10.3390/cancers12113362. Cancers (Basel). 2020. PMID: 33202923 Free PMC article.
High-resolution array-based comparative genomic hybridization of bladder cancers identifies mouse double minute 4 (MDM4) as an amplification target exclusive of MDM2 and TP53.
Veerakumarasivam A, Scott HE, Chin SF, Warren A, Wallard MJ, Grimmer D, Ichimura K, Caldas C, Collins VP, Neal DE, Kelly JD. Veerakumarasivam A, et al. Clin Cancer Res. 2008 May 1;14(9):2527-34. doi: 10.1158/1078-0432.CCR-07-4129. Clin Cancer Res. 2008. PMID: 18451213 Free article.
Loss of expression of the tumour suppressor gene AIMP3 predicts survival following radiotherapy in muscle-invasive bladder cancer.
Gurung PM, Veerakumarasivam A, Williamson M, Counsell N, Douglas J, Tan WS, Feber A, Crabb SJ, Short SC, Freeman A, Powles T, Hoskin PJ, West CM, Kelly JD. Gurung PM, et al. Among authors: veerakumarasivam a. Int J Cancer. 2015 Feb 1;136(3):709-20. doi: 10.1002/ijc.29022. Epub 2014 Jul 22. Int J Cancer. 2015. PMID: 24917520 Free article. Clinical Trial.
Calreticulin and cancer.
Zamanian M, Veerakumarasivam A, Abdullah S, Rosli R. Zamanian M, et al. Among authors: veerakumarasivam a. Pathol Oncol Res. 2013 Apr;19(2):149-54. doi: 10.1007/s12253-012-9600-2. Epub 2013 Feb 8. Pathol Oncol Res. 2013. PMID: 23392843 Free article. Review.
Evaluation of CERS2 Gene as a Potential Biomarker for Bladder Cancer.
Aldoghachi AF, Baharudin A, Ahmad U, Chan SC, Ong TA, Yunus R, Razack AH, Yusoff K, Veerakumarasivam A. Aldoghachi AF, et al. Among authors: veerakumarasivam a. Dis Markers. 2019 Sep 15;2019:3875147. doi: 10.1155/2019/3875147. eCollection 2019. Dis Markers. 2019. PMID: 31636736 Free PMC article.
Differential expression of selected histone modifier genes in human solid cancers.
Ozdağ H, Teschendorff AE, Ahmed AA, Hyland SJ, Blenkiron C, Bobrow L, Veerakumarasivam A, Burtt G, Subkhankulova T, Arends MJ, Collins VP, Bowtell D, Kouzarides T, Brenton JD, Caldas C. Ozdağ H, et al. Among authors: veerakumarasivam a. BMC Genomics. 2006 Apr 25;7:90. doi: 10.1186/1471-2164-7-90. BMC Genomics. 2006. PMID: 16638127 Free PMC article.
43 results